# Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

> **NCT03649841** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 10 (actual)

## Conditions studied

- Castration-Sensitive Prostate Carcinoma
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Prostate Small Cell Neuroendocrine Carcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Antiandrogen Therapy
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03649841
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-29
- **Primary completion:** 2022-09-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Terminated due to low accrual.
- **Last updated:** 2023-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03649841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03649841, "Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03649841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*